Related Experiment Videos
Sentinel lymph node biopsy in patients with thin melanoma
Julie B Lowe1, Eva Hurst, Jeffrey F Moley
1Divisions of Dermatology and Surgical Oncology, Washington University School of Medicine, St Louis, MO, USA.
Archives of Dermatology
|May 21, 2003
Summary
Sentinel lymph node biopsy in thin melanomas (≤1 mm) identified a 7% rate of positive nodes. Higher Clark levels (III+) may indicate a need for this procedure in early-stage melanoma patients.
Area of Science:
- Oncology
- Dermatology
- Surgical Pathology
Background:
- Melanoma staging is crucial for treatment decisions.
- Sentinel lymph node biopsy (SLNB) is a key staging procedure.
- Identifying risk factors for lymph node metastasis in thin melanomas is important.
Purpose of the Study:
- To determine the percentage of positive SLNBs in patients with melanomas ≤1 mm in depth.
- To identify risk factors associated with lymph node disease in this patient group.
Main Methods:
- Retrospective chart review of 46 patients with melanomas ≤1 mm.
- Analysis of SLNB results and associated clinicopathological factors.
- Data collected from a melanoma referral center between 1996 and 2002.
Main Results:
- The SLNB procedure was well-tolerated with no complications.
- 3 out of 46 patients (7%) had positive sentinel lymph nodes (micrometastatic disease).
- A Clark level of III or higher was associated with positive SLNB findings (P≤.07).
Conclusions:
- Study findings are limited by a small sample size.
- SLNB may be indicated for thin melanomas (≤1 mm) with a Clark level of III or higher.
- Further research is warranted to confirm these findings in larger cohorts.